Add Yahoo as a preferred source to see more of our stories on Google. In people with type 1 diabetes, insulin must be taken every day as their pancreas cannot produce the hormone itself. However a new ...

Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the ...

The approval of Eli Lilly’s Mounjaro (tirzepatide) KwikPen by India’s Central Drugs Standard Control Organisation (CDSCO) marks a significant development in diabetes and obesity management, not only ...

One trial found that using injectable insulin icodec once a week was as effective as using a standard injectable form of insulin once a day. The other trial found that it seems to be safe and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Insulin efsitora was noninferior to once-daily insulins ...

Results showed treatment with insulin efsitora was noninferior to insulin degludac based on reduction in HbA1c at 52 weeks. Once-weekly insulin efsitora was found to be as effective as daily basal ...

BAGSVÆRD, Denmark and PLAINSBORO, N.J., Sept. 29, 2025 /PRNewswire/ -- Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration ...

With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa. Lilly on Sunday ...

India faces one of the world's largest burdens of type-2 diabetes, with an estimated 101 million adults affected, second only to China. At the same time, obesity and its metabolic consequences are ...